An interventional study of Pantoprazole and Ranitidine in Antiplatelet Effect, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-04-11.
Sponsored by Seoul National University Bundang Hospital · Not applicable, Interventional, and Supportive care
The investigators sought to evaluate the influence of pantoprazole, indicated as less effective than other proton pump inhibitors, on the antiplatelet effect of clopidogrel, with stratification of the population according to the presence of cytochrome (CYP) 2C19 polymorphism.
Participants being treated with a maintenance dose of 75 mg clopidogrel and 100 mg aspirin daily after previous PCI with coronary stenting were included in the study. Participants were randomly assigned to either the pantoprazole 40 mg once-daily group or the ranitidine 150 mg twice-daily group using a computer-generated randomized table. An independent investigator generated the random allocation sequence. Blood samples were collected at 9:00 on day prior to treatment (day 0) and on day 9. Measuring impedance was performed by one independent investigator in a blinded manner.
Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All participants had a normal platelet count (150,000-450,000/mL).
Exclusion Criteria:
Drug: Pantoprazole 40 mg once-daily
Drug: Pantoprazole
Drug: Ranitidine 150 mg twice-daily
Drug: Ranitidine
pantoprazole 40 mg once-daily
ranitidine 150 mg twice-daily
Number of participants with more than 5 Ω of impedance after intervention by an aggregometer which measures platelet aggregation in whole blood samples
8 days after administration of pantoprazole (or ranitidine)
Time frame: 8 days
Change of the impedance value (Ω) by an aggregometer which measures platelet aggregation in whole blood samples
8 days after administration of pantoprazole (or ranitidine)
Time frame: baseline and 8days
Number of participants with gastrointestinal bleeding
Time frame: up to 2weeks
Number of participants with reccured coronary artery disease
Time frame: up to 2weeks
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Bundang Hospital